Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Analysis

Early Outcome of a Phase I/II Clinical Trial (NCT03538899) of Gene-Corrected Autologous CD34+ Hematopoietic Cells and Low-Exposure Busulfan in Newly Diagnosed Patients with Artemis-Deficient Severe Combined Immunodeficiency (ART-SCID)

Clinical Outcomes of CLL Patients with Relapsed or Refractory Disease after CD19-Specific CAR-T Therapy

Outcomes in Patients with Therapy-Related Acute Myeloid Leukemia (t-AML) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Analysis

Mgta-456 Cell Therapy in Inherited Metabolic Disease (IMD) Yields Rapid and Durable Long-Term Improvement of Disease-Specific Outcomes in a Phase 2 Trial

A Prospective Phase II Clinical Trial of CD26/Dipeptidyl Peptidase (DPP)-IV Inhibition for Prevention of Acute Graft Versus Host Disease (aGVHD) Following Myeloablative Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation.

Addition of Tocilizumab to Cyclosporine-a/ Mycophenolate Mofetil (CSA/ MMF) Graft-Vs-Host Disease (GVHD) Prophylaxis Significantly Abrogates Pre-Engraftment Syndrome (PES) & Severe Acute Gvhd after Adult Double Unit Cord Blood Transplantation (dCBT)

Risk-Adapted Preemptive Tocilizumab Decreases Severe Cytokine Release Syndrome (CRS) after CTL019 CD19-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for Pediatric B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Phase II Trial of Pasireotide to Prevent GI Toxicity and Acute Gvhd in Allogeneic HSCT

Lentiglobin for Sickle Cell Disease (SCD) Gene Therapy (GT): Updated Results in Group C Patients from the Phase 1/2 Hgb-206 Study

A Phase II Study of Sirolimus-Based Calcineurin Inhibitor-Free Gvhd Prophylaxis after Peripheral Blood Haploidentical Transplantation with Post-Transplant Cyclophosphamide

Transplant Referral Patterns for Patients (Pts) with Newly Diagnosed (ND) Higher-Risk (HR) Myelodysplastic Syndromes (MDS), and European Leukemianet (ELN) 2010 Intermediate-Risk (IR) or Adverse-Risk (AR) Acute Myeloid Leukemia (AML) in the Connect® MDS/AML Registry

Efficacy and Safety of CPX-351 Versus 7+3 in a Phase 3 Exploratory Analysis in Patients with High-Risk/Secondary Acute Myeloid Leukemia (sAML) with Prior Hypomethylating Agent (HMA) Exposure Who Achieved Remission

Targeting Danger Associated Molecular Pattern (DAMP) with CD24Fc to Reduce Acute Gvhd: Study Design on a Randomized Double Blind Placebo Controlled Phase III Clinical Trial (CATHY Study)

Clinical Outcomes and Characteristics of Patients (pts) with FLT3–Internal Tandem Duplication (FLT3-ITD)–Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Undergoing Hematopoietic Stem Cell Transplant (HSCT) after Quizartinib (Q) or Salvage Chemotherapy (SC) in the Quantum-R Trial